H Lundbeck A/S (HLUN-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, H Lundbeck A/S (HLUN-B) has a cash flow conversion efficiency ratio of 0.014x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr338.00 Million ≈ $52.88 Million USD) by net assets (Dkr24.90 Billion ≈ $3.90 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
H Lundbeck A/S - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how H Lundbeck A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
H Lundbeck A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of H Lundbeck A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arcosa Inc
NYSE:ACA
|
0.046x |
|
YASKAWA ELEC. UNSP. ADR 2
F:YEC0
|
N/A |
|
Floor & Decor Holdings Inc
NYSE:FND
|
0.043x |
|
PrairieSky Royalty Ltd
TO:PSK
|
0.033x |
|
Hong Leong Financial Group Bhd
KLSE:1082
|
0.055x |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
0.197x |
|
Landstar System Inc
NASDAQ:LSTR
|
0.112x |
|
Maha Properti Indonesia Tbk PT
JK:MPRO
|
-0.003x |
Annual Cash Flow Conversion Efficiency for H Lundbeck A/S (2004–2025)
The table below shows the annual cash flow conversion efficiency of H Lundbeck A/S from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Dkr24.90 Billion ≈ $3.90 Billion |
Dkr4.90 Billion ≈ $766.33 Million |
0.197x | +47.90% |
| 2024-12-31 | Dkr25.01 Billion ≈ $3.91 Billion |
Dkr3.33 Billion ≈ $520.38 Million |
0.133x | -28.14% |
| 2023-12-31 | Dkr22.05 Billion ≈ $3.45 Billion |
Dkr4.08 Billion ≈ $638.35 Million |
0.185x | +9.28% |
| 2022-12-31 | Dkr20.78 Billion ≈ $3.25 Billion |
Dkr3.52 Billion ≈ $550.57 Million |
0.169x | +36.25% |
| 2021-12-31 | Dkr18.28 Billion ≈ $2.86 Billion |
Dkr2.27 Billion ≈ $355.47 Million |
0.124x | -45.02% |
| 2020-12-31 | Dkr16.97 Billion ≈ $2.66 Billion |
Dkr3.84 Billion ≈ $600.33 Million |
0.226x | +26.11% |
| 2019-12-31 | Dkr14.55 Billion ≈ $2.28 Billion |
Dkr2.61 Billion ≈ $408.20 Million |
0.179x | -57.29% |
| 2018-12-31 | Dkr14.25 Billion ≈ $2.23 Billion |
Dkr5.98 Billion ≈ $935.77 Million |
0.420x | +26.38% |
| 2017-12-31 | Dkr12.18 Billion ≈ $1.91 Billion |
Dkr4.04 Billion ≈ $632.87 Million |
0.332x | +2.98% |
| 2016-12-31 | Dkr9.69 Billion ≈ $1.52 Billion |
Dkr3.13 Billion ≈ $489.09 Million |
0.322x | +1338.01% |
| 2015-12-31 | Dkr8.79 Billion ≈ $1.37 Billion |
Dkr197.00 Million ≈ $30.82 Million |
0.022x | -81.16% |
| 2014-12-31 | Dkr13.53 Billion ≈ $2.12 Billion |
Dkr1.61 Billion ≈ $251.90 Million |
0.119x | -57.32% |
| 2013-12-31 | Dkr13.48 Billion ≈ $2.11 Billion |
Dkr3.76 Billion ≈ $588.28 Million |
0.279x | +74.29% |
| 2012-12-31 | Dkr13.20 Billion ≈ $2.06 Billion |
Dkr2.11 Billion ≈ $330.44 Million |
0.160x | -43.59% |
| 2011-12-31 | Dkr12.78 Billion ≈ $2.00 Billion |
Dkr3.62 Billion ≈ $567.00 Million |
0.284x | -3.37% |
| 2010-12-31 | Dkr11.12 Billion ≈ $1.74 Billion |
Dkr3.27 Billion ≈ $510.83 Million |
0.294x | -14.82% |
| 2009-12-31 | Dkr8.80 Billion ≈ $1.38 Billion |
Dkr3.03 Billion ≈ $474.69 Million |
0.345x | -5.88% |
| 2008-12-31 | Dkr7.59 Billion ≈ $1.19 Billion |
Dkr2.78 Billion ≈ $434.98 Million |
0.366x | -2.72% |
| 2007-12-31 | Dkr7.18 Billion ≈ $1.12 Billion |
Dkr2.70 Billion ≈ $423.19 Million |
0.376x | +82.69% |
| 2006-12-31 | Dkr6.76 Billion ≈ $1.06 Billion |
Dkr1.39 Billion ≈ $218.10 Million |
0.206x | -25.47% |
| 2005-12-31 | Dkr7.49 Billion ≈ $1.17 Billion |
Dkr2.07 Billion ≈ $324.10 Million |
0.277x | -19.06% |
| 2004-12-31 | Dkr7.84 Billion ≈ $1.23 Billion |
Dkr2.68 Billion ≈ $418.96 Million |
0.342x | -- |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more